A MuSK-ellenes antitest pozitív myasthenia gravis kezelése

Translated title of the contribution: Treatment of anti-MuSK antibody positive myasthenia gravis

Zsuzsanna Pál, Judit Boczán, B. Bereznai, Gábor Lovas, Mária Judit Molnár

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The authors report the case of a 27-year-old woman with muscle-specific receptor tyrosine kinase antibody positive myasthenia with predominantly ocular and bulbar symptoms. Both edrophonium and low dose (4×30 mg/day) pyridostigmin resulted in cholinergic side effects including fasciculation mainly in the facial and neck muscles, and excessive salivation. The patient responded well to a relatively high dose of chronic corticosteroid treatment (methyprednisolone 64mg/day), but the decrease of the corticosteroid dose below 16 mg/day induced exacerbation of the clinical symptoms. Immunosuppression with azathioprine and methotrexate failed to maintain the clinical improvement. However, plasma exchange was always very effective, and all clinical symptoms improved significantly. The authors conclude that patients with muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis should have an individual treatment protocol differing from those used in patients who do not have this antibody but are positive for acetylcholine-receptor antibody. Identification of the pathogenic antibody in the early stage of myasthenia gravis may help to develop the optimal, individualized treatment strategy, to avoid severe side effects, and to achieve fast improvement. Orv. Hetil., 2011, 152, 1586-1589.

Original languageHungarian
Pages (from-to)1586-1589
Number of pages4
JournalOrvosi Hetilap
Volume152
Issue number39
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

Myasthenia Gravis
Anti-Idiotypic Antibodies
Antibodies
Receptor Protein-Tyrosine Kinases
Adrenal Cortex Hormones
Edrophonium
Facial Muscles
Fasciculation
Neck Muscles
Salivation
Therapeutics
Muscles
Plasma Exchange
Azathioprine
Cholinergic Receptors
Clinical Protocols
Methotrexate
Immunosuppression
Cholinergic Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A MuSK-ellenes antitest pozitív myasthenia gravis kezelése. / Pál, Zsuzsanna; Boczán, Judit; Bereznai, B.; Lovas, Gábor; Molnár, Mária Judit.

In: Orvosi Hetilap, Vol. 152, No. 39, 01.09.2011, p. 1586-1589.

Research output: Contribution to journalArticle

Pál, Z, Boczán, J, Bereznai, B, Lovas, G & Molnár, MJ 2011, 'A MuSK-ellenes antitest pozitív myasthenia gravis kezelése', Orvosi Hetilap, vol. 152, no. 39, pp. 1586-1589. https://doi.org/10.1556/OH.2011.29177
Pál, Zsuzsanna ; Boczán, Judit ; Bereznai, B. ; Lovas, Gábor ; Molnár, Mária Judit. / A MuSK-ellenes antitest pozitív myasthenia gravis kezelése. In: Orvosi Hetilap. 2011 ; Vol. 152, No. 39. pp. 1586-1589.
@article{5f56d1835b4341829bd39fc3de9c8b60,
title = "A MuSK-ellenes antitest pozit{\'i}v myasthenia gravis kezel{\'e}se",
abstract = "The authors report the case of a 27-year-old woman with muscle-specific receptor tyrosine kinase antibody positive myasthenia with predominantly ocular and bulbar symptoms. Both edrophonium and low dose (4×30 mg/day) pyridostigmin resulted in cholinergic side effects including fasciculation mainly in the facial and neck muscles, and excessive salivation. The patient responded well to a relatively high dose of chronic corticosteroid treatment (methyprednisolone 64mg/day), but the decrease of the corticosteroid dose below 16 mg/day induced exacerbation of the clinical symptoms. Immunosuppression with azathioprine and methotrexate failed to maintain the clinical improvement. However, plasma exchange was always very effective, and all clinical symptoms improved significantly. The authors conclude that patients with muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis should have an individual treatment protocol differing from those used in patients who do not have this antibody but are positive for acetylcholine-receptor antibody. Identification of the pathogenic antibody in the early stage of myasthenia gravis may help to develop the optimal, individualized treatment strategy, to avoid severe side effects, and to achieve fast improvement. Orv. Hetil., 2011, 152, 1586-1589.",
keywords = "anti MuSK antibody, myasthenia gravis, personalized medicine",
author = "Zsuzsanna P{\'a}l and Judit Bocz{\'a}n and B. Bereznai and G{\'a}bor Lovas and Moln{\'a}r, {M{\'a}ria Judit}",
year = "2011",
month = "9",
day = "1",
doi = "10.1556/OH.2011.29177",
language = "Hungarian",
volume = "152",
pages = "1586--1589",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "39",

}

TY - JOUR

T1 - A MuSK-ellenes antitest pozitív myasthenia gravis kezelése

AU - Pál, Zsuzsanna

AU - Boczán, Judit

AU - Bereznai, B.

AU - Lovas, Gábor

AU - Molnár, Mária Judit

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The authors report the case of a 27-year-old woman with muscle-specific receptor tyrosine kinase antibody positive myasthenia with predominantly ocular and bulbar symptoms. Both edrophonium and low dose (4×30 mg/day) pyridostigmin resulted in cholinergic side effects including fasciculation mainly in the facial and neck muscles, and excessive salivation. The patient responded well to a relatively high dose of chronic corticosteroid treatment (methyprednisolone 64mg/day), but the decrease of the corticosteroid dose below 16 mg/day induced exacerbation of the clinical symptoms. Immunosuppression with azathioprine and methotrexate failed to maintain the clinical improvement. However, plasma exchange was always very effective, and all clinical symptoms improved significantly. The authors conclude that patients with muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis should have an individual treatment protocol differing from those used in patients who do not have this antibody but are positive for acetylcholine-receptor antibody. Identification of the pathogenic antibody in the early stage of myasthenia gravis may help to develop the optimal, individualized treatment strategy, to avoid severe side effects, and to achieve fast improvement. Orv. Hetil., 2011, 152, 1586-1589.

AB - The authors report the case of a 27-year-old woman with muscle-specific receptor tyrosine kinase antibody positive myasthenia with predominantly ocular and bulbar symptoms. Both edrophonium and low dose (4×30 mg/day) pyridostigmin resulted in cholinergic side effects including fasciculation mainly in the facial and neck muscles, and excessive salivation. The patient responded well to a relatively high dose of chronic corticosteroid treatment (methyprednisolone 64mg/day), but the decrease of the corticosteroid dose below 16 mg/day induced exacerbation of the clinical symptoms. Immunosuppression with azathioprine and methotrexate failed to maintain the clinical improvement. However, plasma exchange was always very effective, and all clinical symptoms improved significantly. The authors conclude that patients with muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis should have an individual treatment protocol differing from those used in patients who do not have this antibody but are positive for acetylcholine-receptor antibody. Identification of the pathogenic antibody in the early stage of myasthenia gravis may help to develop the optimal, individualized treatment strategy, to avoid severe side effects, and to achieve fast improvement. Orv. Hetil., 2011, 152, 1586-1589.

KW - anti MuSK antibody

KW - myasthenia gravis

KW - personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=80053366277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053366277&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29177

DO - 10.1556/OH.2011.29177

M3 - Article

C2 - 21920845

AN - SCOPUS:80053366277

VL - 152

SP - 1586

EP - 1589

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 39

ER -